| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses JH Krystal, LP Karper, JP Seibyl, GK Freeman, R Delaney, JD Bremner, ... Archives of general psychiatry 51 (3), 199-214, 1994 | 4209 | 1994 |
| MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder JD Bremner, P Randall, TM Scott, RA Bronen, JP Seibyl, SM Southwick, ... The American journal of psychiatry 152 (7), 973, 1995 | 2446 | 1995 |
| Levodopa and the progression of Parkinson's disease Parkinson Study Group New England Journal of Medicine 351 (24), 2498-2508, 2004 | 2386 | 2004 |
| The Parkinson progression marker initiative (PPMI) K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ... Progress in neurobiology 95 (4), 629-635, 2011 | 1743 | 2011 |
| Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. M Laruelle, A Abi-Dargham, CH Van Dyck, R Gil, CD D'Souza, J Erdos, ... Proceedings of the National Academy of Sciences 93 (17), 9235-9240, 1996 | 1660 | 1996 |
| Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort A Abi-Dargham, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, ... American journal of psychiatry 155 (6), 761-767, 1998 | 1137 | 1998 |
| Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. RG Holloway, I Shoulson, S Fahn, K Kieburtz, A Lang, K Marek, ... Archives of neurology 61 (7), 1044-1053, 2004 | 697 | 2004 |
| CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimer's & dementia 14 (11), 1470-1481, 2018 | 677 | 2018 |
| Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study H Barthel, HJ Gertz, S Dresel, O Peters, P Bartenstein, K Buerger, ... The Lancet Neurology 10 (5), 424-435, 2011 | 652 | 2011 |
| Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography RT Malison, LH Price, R Berman, CH van Dyck, GH Pelton, L Carpenter, ... Biological psychiatry 44 (11), 1090-1098, 1998 | 632 | 1998 |
| Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale RA Sewell, EB Perry Jr, LP Karper, MD Bell, P Lysaker, JL Goulet, ... Schizophrenia research 124 (1-3), 1-12, 2010 | 582 | 2010 |
| Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease JP Seibyl, KL Marchek, D Quinlan, K Sheff, S Zoghbi, Y Zea‐Ponce, ... Annals of Neurology: Official Journal of the American Neurological …, 1995 | 574 | 1995 |
| Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study O Sabri, MN Sabbagh, J Seibyl, H Barthel, H Akatsu, Y Ouchi, K Senda, ... Alzheimer's & dementia 11 (8), 964-974, 2015 | 561 | 2015 |
| The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ... Annals of clinical and translational neurology 5 (12), 1460-1477, 2018 | 484 | 2018 |
| Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. RB Innis, JP Seibyl, BE Scanley, M Laruelle, A Abi-Dargham, E Wallace, ... Proceedings of the National Academy of Sciences 90 (24), 11965-11969, 1993 | 472 | 1993 |
| [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease KL Marek, JP Seibyl, SS Zoghbi, Y Zea-Ponce, RM Baldwin, B Fussell, ... Neurology 46 (1), 231-237, 1996 | 471 | 1996 |
| Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson … JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ... JAMA neurology 70 (10), 2013 | 456 | 2013 |
| [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression K Marek, R Innis, C Van Dyck, B Fussell, M Early, S Eberly, D Oakes, ... Neurology 57 (11), 2089-2094, 2001 | 435 | 2001 |
| Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects AD Joshi, MJ Pontecorvo, CM Clark, AP Carpenter, DL Jennings, ... Journal of Nuclear Medicine 53 (3), 378-384, 2012 | 408 | 2012 |
| Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study A Siderowf, L Concha-Marambio, DE Lafontant, CM Farris, Y Ma, ... The Lancet Neurology 22 (5), 407-417, 2023 | 401 | 2023 |
